Novavax
NVAX
#5751
Rank
$1.12 B
Marketcap
$6.91
Share price
0.73%
Change (1 day)
-16.75%
Change (1 year)

Revenue for Novavax (NVAX)

Revenue in 2025 (TTM): $1.02 Billion USD

According to Novavax's latest financial reports the company's current revenue (TTM ) is $1.02 Billion USD. In 2024 the company made a revenue of $0.68 Billion USD a decrease over the revenue in the year 2023 that were of $0.69 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Novavax from 1996 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) $1.02 B50.16%
2024 $0.68 B-1.63%
2023 $0.69 B-50.23%
2022 $1.39 B21.56%
2021 $1.14 B141.02%
2020 $0.47 B2448.48%
2019 $18.66 M-45.57%
2018 $34.28 M9.98%
2017 $31.17 M103.06%
2016 $15.35 M-57.65%
2015 $36.25 M18.24%
2014 $30.65 M46.6%
2013 $20.91 M-5.26%
2012 $22.07 M50.3%
2011 $14.68 M4182.22%
2010 $0.34 M5.54%
2009 $0.32 M-69.45%
2008 $1.06 M-18.47%
2007 $1.3 M-72.13%
2006 $4.68 M-36.61%
2005 $7.38 M-17.21%
2004 $8.92 M-24.28%
2003 $11.78 M-17.02%
2002 $14.2 M-40.98%
2001 $24.06 M872.36%
2000 $2.47 M106.25%
1999 $1.2 M71.43%
1998 $0.7 M16.67%
1997 $0.6 M100%
1996 $0.3 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Agenus
AGEN
$0.10 B-89.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
$2.41 B 135.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
$0.75 B-26.71%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
$0.59 B-41.44%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
$58.12 B 5,574.64%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
$62.78 B 6,029.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
$56.37 B 5,403.30%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
$42.35 B 4,034.68%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
$2.6 M-99.75%๐Ÿ‡บ๐Ÿ‡ธ USA